Cargando…

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jinyang, Dong, Feng, He, You, Xia, Xianyou, Cheng, Fangling, Chen, Sui, Hou, Xiaoshuang, Zhang, Po, Liu, Guohao, Li, Ying, Gao, Qian, Dong, Minhai, Li, Ting, Li, Wei, Xiao, Qungen, Li, Xiaopeng, Yu, Xingjiang, Xi, Guifa, Guo, Dongsheng, Wu, Xudong, Wang, Baofeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472135/ https://www.ncbi.nlm.nih.gov/pubmed/36096529 http://dx.doi.org/10.1136/jitc-2021-004452

Ejemplares similares

The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
por: Cheng, Fangling, et al.
Publicado: (2019)

Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
por: Cheng, Fangling, et al.
Publicado: (2020)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling
por: Xiao, Qungen, et al.
Publicado: (2018)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling
por: Xiao, Qungen, et al.
Publicado: (2019)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling
por: Xiao, Qungen, et al.
Publicado: (2022)

FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells
por: Liu, Guohao, et al.
Publicado: (2023)

Soluble LRIG2 Ectodomain Is Released from Glioblastoma Cells and Promotes the Proliferation and Inhibits the Apoptosis of Glioblastoma Cells In Vitro and In Vivo in a Similar Manner to the Full-Length LRIG2
por: Xiao, Qungen, et al.
Publicado: (2014)

Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas
por: Zhang, Po, et al.
Publicado: (2022)

BRCA1 deficiency in mature CD8(+) T lymphocytes impairs antitumor immunity
por: Wu, Bogang, et al.
Publicado: (2023)

MDSCs-derived GPR84 induces CD8(+) T-cell senescence via p53 activation to suppress the antitumor response
por: Liu, Jinyan, et al.
Publicado: (2023)

Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype
por: Dong, Hongliang, et al.
Publicado: (2020)

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity
por: Kalim, Khalid W, et al.
Publicado: (2022)

Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth
por: Li, Youwei, et al.
Publicado: (2023)

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer
por: Ji, Dengbo, et al.
Publicado: (2020)

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
por: Cueto, Francisco J, et al.
Publicado: (2021)

Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells
por: Noyes, David, et al.
Publicado: (2022)

Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity
por: Wang, Zining, et al.
Publicado: (2021)

Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity
por: Ye, Jun, et al.
Publicado: (2021)

Amino acids and RagD potentiate mTORC1 activation in CD8(+) T cells to confer antitumor immunity
por: Zhang, Yiwen, et al.
Publicado: (2021)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

IL-31 induces antitumor immunity in breast carcinoma
por: Kan, Tal, et al.
Publicado: (2020)

Estrogen receptor beta signaling in CD8(+) T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch
por: Yuan, Bin, et al.
Publicado: (2021)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity
por: Xi, Qing, et al.
Publicado: (2020)

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
por: Won, Ji Eun, et al.
Publicado: (2022)

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
por: Efimova, Iuliia, et al.
Publicado: (2020)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics
por: Park, Joo Dong, et al.
Publicado: (2022)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
por: You, Dan, et al.
Publicado: (2021)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes
por: Nishida, Mikako, et al.
Publicado: (2021)

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status
por: Johansson, Mikael, et al.
Publicado: (2013)

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
por: Lee, Eunhee, et al.
Publicado: (2023)

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
por: Torres, Nicolas, et al.
Publicado: (2020)

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
por: Zhang, Cangang, et al.
Publicado: (2021)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
por: Chen, Heyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bnqiui1t5ohn8sojhu31uq1c4m